CD20 Protein, Human, Recombinant (TrxA), Biotinylated

1.Using the Octet RED System, the affinity constant (Kd) of CD20 Protein, Human, Recombinant (TrxA Tag), Biotinylated bound Mabthera was 0.04 μM. 2.Loaded Anti-Human CD20 antibody, human IgG1 on ProA Biosensor, can bind Recombinant Human CD20 Protein, TrxA Tag, Biotinylated with an affinity constant of 14.6 nM as determined in BLI assay (Routinely tested).

CD20 Protein, Human, Recombinant (TrxA), Biotinylated is expressed in E. coli expression system with TrxA tag. The predicted molecular weight is 23.9 kDa and the accession number is A0A024R507.

Human

E. coli

> 80 % as determined by SDS-PAGE.

CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed in all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections, and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells are usually in the normal range but can be very low.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy